I.V. paracetamol is commonly used in children for the management of postoperative pain. Until recently, i.v. administration of paracetamol has been achieved through the use of the pro-drug propacetamol, which requires in vivo hydrolysis by plasma esterases to yield the active form, paracetamol. 1 However, the risks of hypersensitivity and administration site reactions associated with propacetamol pose significant challenges to the optimization of dosage and pain control. 2 -4 Improved stabilization techniques have permitted the development and use of an i.v. form of paracetamol (Perfalgan), which no longer requires the hydrolysis step for activation. 1 Although i.v. paracetamol is frequently used for pain control in children, there is little pharmacokinetic (PK) data in children of different ages. The PK of this new formulation of paracetamol has been assessed in seven children aged 10.3-16.6 yr; 5 however, the small number of children and the narrow age range leave the younger age groups in whom this formulation is frequently used, with insufficient PK data. This lack of PK information is one of the reasons that led the Medicines and Healthcare-product Regulatory Agency in the UK (MHRA-UK) to highlight it as a medicine under surveillance. 6 The aims of the present study were therefore to describe the effects of age and body size on the PK of a single dose of i.v. paracetamol in children under 16 yr of age.
children admitted for elective surgery were approached for recruitment to the study when there was an anticipated need for i.v. paracetamol for postoperative pain relief. Written informed consent was obtained from the parents, and for children above 7 yr old, additional written assent was sought. Eligibility and willingness of a child to take part in the study was determined through a brief interview with the parent, guardian, and/or where appropriate the child. Children with liver dysfunction, renal impairment, and hypersensitivity to paracetamol were excluded after routine preoperative history and examination. General anaesthesia was induced either i.v. with propofol 3.5 mg kg 21 or by a facemask with sevoflurane and maintained with isoflurane. After induction of anaesthesia, where medically indicated, each patient was administered paracetamol i.v. over a 15 min period by the study anaesthetist. The following doses were administered: adolescents over 50 kg body weight-1 g; children, 10-50 kg-15 mg kg 21 body weight; children ,1 yr-7.5 mg kg 21 body weight.
Blood sampling
Blood was sampled from a peripheral line inserted for routine clinical use. Before the paracetamol administration, 30 ml of blood was spotted on to a Guthrie card, ensuring that the blood soaked through to the other side of the card. This sampling procedure was repeated in triplicate at 15, 30, 60 min, 2, 4, 6, and 8 h from the end of the infusion. Blood spotted on to the Guthrie cards was allowed to dry at room temperature overnight, in darkness, and stored in sealed airtight plastic bags at 48C in a secured fridge until chromatographic analysis.
Analysis of paracetamol

Paracetamol extraction
Paracetamol was extracted as described previously. 7 In brief, a 6 mm disc was punched out from the centre of one of the blood spots on the Guthrie card and placed in an Eppendorf micro test tube. To this was added 200 ml of ammonium formate buffer (20 mM, pH 3.5) and 200 ng of 2-acetamidophenol (internal standard) and vortex mixed (Stuart Auto Vortex Mixer SA2, Rhys International Ltd, Greater Manchester, UK) for 2 min. Protein was then precipitated by the addition of 24.6 ml of 30% perchloric acid followed by centrifugation at 13 000g for 5 min. The supernatant was then stored for later use.
Chromatographic analysis
All reagents were purchased from Fisher Scientific, UK. Paracetamol whole-blood concentration was quantified using a high-performance liquid chromatographic assay, with ultraviolet detection based on the method described by Oliveira and colleagues, 7 and validated according to the International Conference on Harmonisation's guidelines for validating analytical methods. 8 In brief, after paracetamol extraction, 20 ml of the supernatant prepared above was introduced onto a Hichrom 3.5 m C18 (100×4.6 mm) column (Hichrom Ltd, Reading, UK) maintained at 258C using a Gilson 231 sample injector (Anachem Ltd, Luton, UK This approach maximized the likelihood for the data above the limit of quantification while treating BQL data as censored.
Population PK modelling of paracetamol
From the 33 children, a total of 159 blood paracetamol concentrations were collected and subjected to PK analysis using non-linear mixed-effects modelling using the software package, NONMEM (version VII, ICON Development Solutions, Ellicott City, MD, USA). PK parameter modelling was performed using the first-order conditional estimation with interaction. Potential models considered were the classical linear one-and two-compartment models, and interindividual variability (IIV) in clearance and volume of distribution were estimated using an exponential scale. The covariance of clearance and volume of distribution IIV was also incorporated into the model. Residual variability was estimated only by the proportional component since the additive component was close to 0 and hence ignored. The equation for the residual variability was as follows:
To enable comparison of the paediatric PK parameter estimates with adult values, the parameters obtained were standardized to adult weight using allometric-size scaling. Clearance (CL, in litres per hour), inter-compartmental clearance (Q, in the case of a two-compartment model), and apparent volumes of distribution (V 1 and V 2 , in litres) were scaled to a weight of 70 kg as follows:
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where WT i is the weight of the ith child and u the population parameter estimate of an adult with weight 70 kg. Significant covariates were identified throughout the process of model building and evaluation, by both visual examination of the scatter plots of conditional IIV obtained for each PK parameter vs each covariate and the improvement in the goodness of fit of the model. Forward inclusion of a covariate into the model required a reduction in the objective function value (OFV) of at least 3.84 (which corresponds to P,0.05, d.f.¼1).
The model was evaluated using graphs of residuals and weighted residuals vs predicted paracetamol concentrations. Additionally, measured paracetamol concentrations were plotted separately against the predicted concentrations to visually assess the deviations of the model predicted from observed concentrations. A visual predictive check (VPC) was also generated for the final model and principal component analysis (PCA) performed to investigate any possible subgroups within the patient population which were not identified during the model development.
Results
Thirty-three children aged 1.8 -15 yr of age were recruited to this study (Table 1 ). All the children had a BMI within the range 14.1-25.4 kg m 22 .
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A two-compartment model best described the data, with a marked reduction in the OFV (60.7 units, P¼7×10 215 )
when compared with a one-compartment model. The inclusion of weight as an a priori covariate resulted in significant improvement in the goodness of fit and a 41.5 unit decrease in the OFV (P¼1×10 210 ). In addition, the IIV (CV%) in CL and V 1 were significantly reduced from 34.9% and 72.1% to 26.6% and 63.0%, respectively, by the inclusion of WT as an a priori covariate on clearance and volume parameters in the two-compartment model. The population parameter 
Model evaluation
The plots of observed paracetamol concentrations against both population-and individual-predicted paracetamol concentrations in the final model, Figure 1 , demonstrated a reasonable agreement around the line of identity, although with a slight under-prediction, particularly at higher paracetamol concentrations. There are two possible reasons for the twocompartmental model under-prediction particularly at higher paracetamol concentrations. The first is inherent errors in the blood sampling technique where, despite flushing, traces of administered paracetamol remaining in the peripheral infusion line led to higher concentrations in the early collected samples. A second plausible explanation is that 10-20% of paracetamol is bound to red blood cells which could affect the partitioning of the drug into plasma and hence the blood/plasma ratio of the measured paracetamol concentration particularly at higher concentrations. The scatter plots of residuals vs model-predicted paracetamol concentrations demonstrated that they were randomly distributed and the weighted residuals lay within +2 units of the null ordinate of perfect agreement (Fig. 2) . Results for the evaluation of predictive performance of the final model obtained from the full data set, using a VPC, are demonstrated in Figure 3 .
In order to test the overall influence of any individual on model parameters, the matrix of the standardized structural parameters and variance components was subjected to PCA and the determinant of this matrix was used to test for multi-collinearity in the data. A determinant value of 0.05 (considerably greater than the limit of 1×10 25 ) indicated that multi-collinearity is not a problem for the data, that is, none of the correlation coefficients was particularly large. PCA resulted in extraction of four components that explained over 80% of the variance in parameter estimates of the final model. The results of PCA did not ascertain any underlying trends not identified by earlier analysis, thus giving evidence for validity of the final model.
Discussion
This report describes the population PK of a new formulation of i.v. paracetamol in children aged 1.8-15 yr. The two- compartment model with first-order elimination best fitted our data. Earlier PK studies that involved i.v. administered proparacetamol in both adults and children have also reported a two-compartment model to be most appropriate. 5 11 The PK parameters we obtained for paracetamol in this study agree closely with those derived from propacetamol studies performed in children and adults. 3 12-15 Patient covariates such as age, height, BSA, and BMI did not significantly affect any of the PK parameters (CL, V 1 , V 2 , and Q). However, total body weight significantly affected the PK of i.v. paracetamol in the children studied. An effect of age (especially post-menstrual age) has been demonstrated for paracetamol when infants and neonates were studied. 16 17 The lack of an age effect on paracetamol plasma clearance and inter-compartmental clearance, in the current study, is most likely due to the older age of our study population when compared with neonates and infants. This supports the suggestion that the overall mechanisms involved in paracetamol elimination reach adult capacity by the age of 2 yr. 18 Besides the Phase II glucuronidation and sulphonation, Phase I oxidation by hepatic Cytochrome P450 2EI enzymes are also involved in the clearance of paracetamol, especially at higher doses, 23 and there have been reports linking the presence of obesity to increased activity of this enzyme. 24 25 The normal BMI of our patient population rules out a likely contribution from these Phase I enzymes, which are known to reach adult levels from 1 yr of age onwards. 26 The lack of a significant effect of age on the central and peripheral volumes of distribution (V 1 and V 2 ) is also likely to be due to body composition being quite close to adult values in the children that were studied. Dramatic differences in volumes are only seen in neonates. Extracellular water and total body water constitute 60% and 75%, respectively, in neonates and 20% and 50%, respectively, in adults, 27 translating into higher V d for hydrophilic drugs in neonates and young infants when compared with adults. 28 Body size descriptors, such as total body weight, BMI, BSA, and height, have been speculated to play a role in drug disposition, and hence dose determination. However, the particular descriptors that affect the PK of i.v. paracetamol in children have not been reported. In the current study, when total body weight was expressed allometrically and incorporated into population PK analysis, which is the formal method of assessing body size effects on PK parameters, 29 it had a significant effect on the PK of i.v. paracetamol. A recent meta-analysis by Green and Duffull 30 has reported that total body weight best describes the volume of distribution and that these variables have a direct proportionality relationship. This finding supports our current analysis, in which total body weight, scaled to the power 1, significantly affected V 1 and V 2 [V 1 ¼28.4×(WT/70); V 2 ¼13.26×(WT/70)].
The effect of weight on drug elimination is justifiably expected, given the increase in physiological function with increasing body mass. However, the best weight descriptor for the clinically important elimination parameter, clearance, is still elusive, as none of the known descriptors adequately accounts for the route of elimination (renal or hepatic). 30 In the current study, mass expressed as total body weight, scaled to the allometric power 0.75, significantly affected the CL of i.v. paracetamol. Although our present analysis did not include weight expressed in terms of lean body weight (LBW), which has been reported to be the best weight descriptor for CL, 31 the normal body weight of our study population gives credence to our findings.
Conclusion
We have demonstrated that the PK of i.v. paracetamol is not affected by age in children aged 2-15 yr. However, body size described by total body weight in allometric terms significantly affected both clearance and volume of distribution of i.v. paracetamol in children. Due to the limitations of the data, it is not possible to comment on the PK of i.v. paracetamol in children younger than 2 yr of age, although for children above this age, the current dose recommendations based on body weight would seem to be appropriate.
